N-Acetyl Cysteine as an Adjunct in the Treatment of Tuberculosis

Abstract EN

Oxidative stress is a common feature of tuberculosis (TB), and persons with reduced antioxidants are at more risk of TB.

TB patients with relatively severe oxidative stress had also more advanced disease as measured by the Karnofsky performance index.

Since adverse effects from anti-TB drugs are also mediated by free radicals, TB patients are prone to side effects, such as hearing loss.

In previous articles, researchers appealed for clinical trials aiming at evaluating N-acetyl cysteine (NAC) in attenuating the dreaded hearing loss during multidrug-resistant TB (MDR-TB) treatment.

However, before embarking on such trials, considerations of NAC’s overall impact on TB treatment are crucial.

Unfortunately, such a comprehensive report on NAC is missing in the literature and this manuscript reviews the broader effect of NAC on TB treatment.

This paper discusses NAC’s effect on mycobacterial clearance, hearing loss, drug-induced liver injury, and its interaction with anti-TB drugs.

Based on the evidence accrued to date, NAC appears to have various beneficial effects on TB treatment.

However, despite the favorable interaction between NAC and first-line anti-TB drugs, the interaction between the antioxidant and some of the second-line anti-TB drugs needs further investigations.